<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176485</url>
  </required_header>
  <id_info>
    <org_study_id>1409505107</org_study_id>
    <nct_id>NCT03176485</nct_id>
  </id_info>
  <brief_title>Evaluation of Pathway Modulation by Raf, MEK, &amp; Kinase Inhibitors</brief_title>
  <official_title>Pilot Study to Evaluate the Signaling Pathway Modulation Demonstrated by Raf, MEK, and Kinase Inhibitors In Human Skin With or Without Solar Simulated Light</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study designed to evaluate the cutaneous effect of systemic inhibition of the
      tyrosine kinase pathway in the presence or absence of solar simulated light exposure.

      A maximum of 45 subjects will be accrued into the overall study we anticipate approximately
      25 patients in the Raf inhibitor group and 10 patients each into the Tyrosine Kinase and MEK
      inhibitor arms of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the modulatory effect of systemic Raf inhibition in the MEK/ERK and
      PI3 /Akt/mTOR pathways in patients undergoing targeted therapy for metastatic disease.

      Changes in relevant proteins will be evaluated using a combined protein expression
      methodology that in includes immunohistochemistry (IHC) and reverse phase protein microarray
      (RPPA) technology.

      The primary endpoint of this study will be assessed in normal skin and skin acutely exposed
      to solar simulated light
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2014</start_date>
  <completion_date type="Anticipated">April 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modulatory effect of systemic Raf inhibition in the MEK/Erk and PI3 /AKT/mTOR pathways in patients undergoing targeted therapy for metastatic disease</measure>
    <time_frame>2 months</time_frame>
    <description>The primary endpoint of the study is to evaluate the modulatory effect of systemic Raf inhibition in the MEK/Erk and PI3 /AKT/mTOR pathways in patients undergoing targeted therapy for metastatic disease. Changes in relevant proteins will be evaluated using a combined protein expression methodology that in includes immunohistochemistry (IHC) and reverse phase protein microarray (RPPA) technology. The primary endpoint of this study will be assessed in normal skin and skin acutely exposed to solar simulated light.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Downstream modulation of direct Ras and MEK inhibition in human keratinocytes and melanocytes following acute solar simulated light exposure in the presence of metastatic disease treatment with Tyrosine kinase and MEK inhibitors.</measure>
    <time_frame>2 months</time_frame>
    <description>The modulatory effect will be evaluated using IHC and RPPA technology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulatory effect of systemic Raf inhibition in the MEK/Erk and PI3 /AKT/mTOR pathways in eligible melanocytic nevi.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate the type and severity of cutaneous squamous cell carcinoma development in patients treated with BRaf inhibitors and the modulatory profile identified in the proposed primary endpoint.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of performing solar simulated light studies in patients undergoing Ras inhibition for metastatic disease.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulatory effect of Ras inhibition in Epidermal Growth Factor Receptor (EGFR) and Activating Protein-1 (AP1) signaling pathways (IHC and RPPA).</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Colon Cancer</condition>
  <condition>Differentiated Thyroid Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>HCC</condition>
  <condition>Metastatic Colon Cancer</condition>
  <arm_group>
    <arm_group_label>ArmA: With Solar Simulated Light Exposure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ArmB: With Solar Simulated Light Exposure (Vemurafenib/Dabraf)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this study arm undergo the same procedures as Arm A, with the addition of a blood test for the presence of porphyrins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ArmC: Without Solar Simulated Light Exposure</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Solar Simulator</intervention_name>
    <description>A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.</description>
    <arm_group_label>ArmA: With Solar Simulated Light Exposure</arm_group_label>
    <arm_group_label>ArmB: With Solar Simulated Light Exposure (Vemurafenib/Dabraf)</arm_group_label>
    <other_name>Multiport UV Solar Simulator Model 60</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have not yet initiated but plan to undergo dosing with a Tyrosine Kinase
             inhibitor (TKI) or Raf inhibitor, either alone or with a MEK inhibitor, for treatment
             of metastatic melanoma, colon cancer, hepatic cell carcinoma, or thyroid cancer.

          -  Individuals with normal skin and Fitzpatrick skin type II, III or IV.

          -  Individuals who are willing to limit sun exposure to the body during the study period,
             and who agree to wear protective clothing and SPF 50 broad spectrum sunscreen or
             sunblock on exposed skin when they are outdoors.

          -  Individuals who have the ability to understand and willingness to sign an informed
             consent before initiation of study procedures, after the nature of the study is
             explained to them and they have asked any questions.

          -  Individuals with a Karnofsky Performance Status of at least 80%.

        Exclusion Criteria:

          -  Individuals with any inflammation or irritation of the skin at the test area
             (buttocks), or any skin conditions felt by the study physician to contraindicate
             enrollment.

          -  Individuals with a history of any skin cancer, melanocytic lesions, actinic keratoses
             or actinic damage in the test area are ineligible. History of such conditions at a
             body site other than the test area is not exclusionary if in the opinion of the study
             physician it will not pose a risk to the subject.

          -  Individuals who are immunosuppressed by virtue of medication or disease, as determined
             by the examining study physician. This includes AIDS patients and subjects taking oral
             steroids.

          -  Individuals with active infection, psychiatric illness, or other situations that in
             the opinion of the study physician limit compliance or interfere with the study
             regimen.

          -  Individuals with a history of photosensitive diseases including, but not limited to,
             Lupus Erythematosus, pseudoporphyria, or other diseases that in the opinion of the
             study physician would pose a risk to the subject or interfere with the study.

          -  Individuals who have used photosensitizing drugs within the last 30 days prior to
             study enrollment, or who will be using a photosensitizing drug during the time of the
             study.

          -  Individuals who have used any topical medication other than emollients on the test
             area within 30 days prior to study enrollment.

          -  Individuals who have used retinoids, steroids, 5-fluorouracil, Levulan, Vaniqua
             (eflornithine), Solaraze, or Imiquimod (AldaraÂ®) anywhere on the body within 30 days
             prior to enrollment.

          -  Individuals must not take mega-doses of vitamins. Mega-doses are defined as more than
             5 capsules of standard multivitamins daily or more than the Tolerable Upper Intake
             Levels of Vitamins, as defined by the Institute of Medicine, National Academy of
             Sciences. Such vitamin therapy must be discontinued at least 30 days prior to study
             entry.

          -  Individuals with a history of natural or artificial sun exposure to the buttocks
             within 30 days of study participation.

          -  Individuals with Fitzpatrick skin type I

          -  Individuals with Fitzpatrick skin type V or VI

          -  Individuals enrolled in or who plan to enroll in a clinical intervention trial. There
             must be a 30-day period between completing a previous study and enrolling in this
             study. The Principal Investigator will have the option to consider an exception for
             patients on drugs of interest for the purpose of this study.

          -  Individuals with a known allergy to lidocaine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara Curiel-Lewandroski</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara Curiel-Lewandroski</last_name>
    <email>ccuriel@email.arizona.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Curiel-Lewandroski</last_name>
      <email>ccuriel@email.arizona.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>melanoma</keyword>
  <keyword>cancer</keyword>
  <keyword>colon</keyword>
  <keyword>thyroid</keyword>
  <keyword>Differentiated</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>RCC</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

